Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, and is generally considered a therapy-recalcitrant disease due to poor response to conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS mutations). However, PDA frequently loses p16ink4a, thereb...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Witkiewicz, Agnieszka K., Borja, Nicholas A., Franco, Jorge, Brody, Jonathan R., Yeo, Charles J., Mansour, John, Choti, Michael A., McCue, Peter, Knudsen, Erik S.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Priority Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599237/
https://ncbi.nlm.nih.gov/pubmed/26158861
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars